Morgan Stanley Tiziana Life Sciences LTD Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Tiziana Life Sciences LTD stock. As of the latest transaction made, Morgan Stanley holds 126,138 shares of TLSA stock, worth $116,046. This represents 0.0% of its overall portfolio holdings.

Number of Shares

126,138

Previous 124,131 1.62%

Holding current value

$116,046

Previous $69,000 18.84%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.42 - $0.61 $842 - $1,224	2,007 Added 1.62%	126,138 $56,000
Q4 2023 Feb 13, 2024	SELL	$0.55 - $0.85 $1,926 - $2,977	-3,503 Reduced 2.74%	124,131 $69,000
Q3 2023 Nov 15, 2023	SELL	$0.6 - $0.82 $1,378 - $1,883	-2,297 Reduced 1.77%	127,634 $84,000
Q2 2023 Aug 14, 2023	BUY	$0.65 - $1.29 $7,673 - $15,229	11,806 Added 9.99%	129,931 $88,000
Q1 2023 May 15, 2023	SELL	$0.51 - $1.1 $12,971 - $27,977	-25,434 Reduced 17.72%	118,125 $128,000

Q4 2022 Feb 14, 2023	SELL	$0.56 - $0.69 $21,526 - $26,524	-38,441 Reduced 21.12%	143,559 $86,000
Q3 2022 Nov 14, 2022	BUY	$0.55 - $0.83 $17,095 - $25,798	31,083 Added 20.6%	182,000 $142,000
Q2 2022 Oct 27, 2022	BUY	$0.66 - $1.06 $36,997 - $59,420	56,057 Added 59.09%	150,917 $112,000
Q2 2022 Aug 15, 2022	BUY	$0.66 - $1.06 $36,997 - $59,420	56,057 Added 59.09%	150,917 $112,000
Q1 2022 Oct 27, 2022	SELL	$0.62 - $1.25 $34,755 - $70,071	-56,057 Reduced 37.14%	94,860 $100,000
Q1 2022 May 13, 2022	SELL	$0.62 - $1.25 $12,305 - $24,810	-19,848 Reduced 17.3%	94,860 $100,000
Q4 2021 Feb 14, 2022	BUY	$0.89 - $1.66 $102,090 - $190,415	114,708 New	114,708 $110,000

Others Institutions Holding TLSA

# of Institutions

Shares Held

816K

Call Options Held

Put Options Held

View Full List

About Tiziana Life Sciences Ltd

Ticker TLSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,273,000
Market Cap $94.1M
Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...

More about TLSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account